Preemptive Surgery for premalignant foregut lesions

Journal of Gastrointestinal Surgery

Volumn 13, Issue 10, 2009, Pages 1874-1887

  Sharma, Rohit R ^a   London, Mark J ^a   Magenta, Laura L ^a   Posner, Mitchell C ^a   Roggin, Kevin K ^a,b  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Foregut; Precancerous; Preemptive; Prophylactic; Surgery

Indexed keywords

BARRETT ESOPHAGUS; BILE DUCT DISEASE; DIGESTIVE SYSTEM TUMOR; GENETIC PREDISPOSITION; GENETICS; HUMAN; PANCREAS TUMOR; PRECANCER; REVIEW; STOMACH TUMOR;

BARRETT ESOPHAGUS; BILE DUCT DISEASES; DIGESTIVE SYSTEM NEOPLASMS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PANCREATIC NEOPLASMS; PRECANCEROUS CONDITIONS; STOMACH NEOPLASMS;

EID: 70350349347     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-009-0935-2     Document Type: Review

References (165)

1. Cameron AJ, Zinsmeister AR, Ballard DJ, Carney JA. Prevalence of columnar-lined (Barrett's) esophagus. Comparison of population-based clinical and autopsy findings. Gastroenterology 1990;99:918-922.
2. Csendes A, Smok G, Burdiles P et al. Prevalence of Barrett's esophagus by endoscopy and histologic studies: a prospective evaluation of 306 control subjects and 376 patients with symptoms of gastroesophageal reflux. Dis Esophagus 2000;13:5-11.
3. Wu PC, Posner MC. The role of surgery in the management of oesophageal cancer. Lancet Oncol 2003;4:481-488.
4. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-831.
5. Dulai GS, Guha S, Kahn KL et al. Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology. 2002;122:26-33.
6. Reid BJ, Levine DS, Longton G et al. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 2000;95:1669-1676.
7. Schnell TG, Sontag SJ, Chejfec G et al. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology 2001;120:1607-1619.
8. Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol 1997;92:212-215.
9. O'Connor JB, Falk GW, Richter JE. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry. Am J Gastroenterol 1999;94:2037-2042.
10. Spechler SJ, Lee E, Ahnen D et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. Jama 2001;285:2331-2338.
11. Skacel M, Petras RE, Gramlich TL et al. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression. Am J Gastroenterol 2000;95:3383-3387.
12. Chow WH, Blaser MJ, Blot WJ et al. An inverse relation between cagA + strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res 1998;58:588-590.
13. Vicari JJ, Peek RM, Falk GW et al. The seroprevalence of cagA-positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease. Gastroenterology 1998;115:50-57.
14. Spechler SJ. Dysplasia in Barrett's esophagus: limitations of current management strategies. Am J Gastroenterol 2005;100:927-935.
15. Collard JM. High-grade dysplasia in Barrett's esophagus. The case for esophagectomy. Chest Surg Clin N Am 2002;12:77-92.
16. Konda VJ, Ross AS, Ferguson MK et al. Is the risk of concomitant invasive esophageal cancer in high-grade dysplasia in Barrett's esophagus overestimated? Clin Gastroenterol Hepatol 2008;6:159-164.
17. Heitmiller RF. Prophylactic esophagectomy in Barrett esophagus with high-grade dysplasia. Langenbecks Arch Surg 2003;388:83-87.
18. Hulscher JB, Tijssen JG, Obertop H, van Lanschot JJ. Transthoracic versus transhiatal resection for carcinoma of the esophagus: a meta-analysis. Ann Thorac Surg 2001;72:306-313.
19. Rindani R, Martin CJ, Cox MR. Transhiatal versus Ivor-Lewis oesophagectomy: is there a difference? Aust N Z J Surg 1999;69:187-194.
20. Peyre CG, DeMeester SR, Rizzetto C et al. Vagal-sparing esophagectomy: the ideal operation for intramucosal adenocarcinoma and barrett with high-grade dysplasia. Ann Surg 2007;246:665-671.
21. de Hoyos A, Litle VR, Luketich JD. Minimally invasive esophagectomy. Surg Clin North Am 2005;85:631-647.
22. Gemmill EH, McCulloch P. Systematic review of minimally invasive resection for gastro-oesophageal cancer. Br J Surg 2007;94:1461-1467.
23. Zingg U, McQuinn A, DiValentino D et al. Minimally invasive versus open esophagectomy for patients with esophageal cancer. Ann Thorac Surg 2009;87:911-919.
24. Luketich JD, Alvelo-Rivera M, Buenaventura PO et al. Minimally invasive esophagectomy: outcomes in 222 patients. Ann Surg 2003;238:486-494.
25. Pennathur A, Luketich JD. Minimally invasive surgical treatment of esophageal carcinoma. Gastrointest Cancer Res 2008;2:295.
26. Altorki NK, Sunagawa M, Little AG, Skinner DB. High-grade dysplasia in the columnar-lined esophagus. Am J Surg 1991;161:97-99. (discussion 99-100).
27. Cameron AJ, Carpenter HC, Laukka MA, Trastek VF. Barrett's esophagus. Pathologic findings following resection for high grade dysplasia. Am J Gastroenterol 1993;88:1483.
28. DeMeester TR, Attwood SE, Smyrk TC et al. Surgical therapy in Barrett's esophagus. Ann Surg 1990;212:528-540. (discussion 540-522).
29. Edwards MJ, Gable DR, Lentsch AB, Richardson JD. The rationale for esophagectomy as the optimal therapy for Barrett's esophagus with high-grade dysplasia. Ann Surg 1996;223:585-589. (discussion 589-591).
30. Hamilton SR, Smith RR. The relationship between columnar epithelial dysplasia and invasive adenocarcinoma arising in Barrett's esophagus. Am J Clin Pathol 1987;87:301-312.
31. Lee RG. Dysplasia in Barrett's esophagus. A clinicopathologic study of six patients. Am J Surg Pathol 1985;9:845-852.
32. Levine DS, Haggitt RC, Blount PL et al. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. Gastroenterology 1993;105:40-50.
33. McArdle JE, Lewin KJ, Randall G, Weinstein W. Distribution of dysplasias and early invasive carcinoma in Barrett's esophagus. Hum Pathol 1992;23:479-482.
34. McDonald ML, Trastek VF, Allen MS et al. Barretts's esophagus: does an antireflux procedure reduce the need for endoscopic surveillance? J Thorac Cardiovasc Surg 1996;111:1135-1138. (discussion 1139-1140).
35. Pera M, Trastek VF, Carpenter HA et al. Barrett's esophagus with high-grade dysplasia: an indication for esophagectomy? Ann Thorac Surg 1992;54:199-204.
36. Peters JH, Clark GW, Ireland AP et al. Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patients. J Thorac Cardiovasc Surg 1994;108:813-821.
37. Reid BJ, Weinstein WM, Lewin KJ et al. Endoscopic biopsy can detect high-grade dysplasia or early adenocarcinoma in Barrett's esophagus without grossly recognizable neoplastic lesions. Gastroenterology 1988;94:81-90.
38. Rice TW, Falk GW, Achkar E, Petras RE. Surgical management of high-grade dysplasia in Barrett's esophagus. Am J Gastroenterol 1993;88:1832-1836.
39. Schmidt HG, Riddell RH, Walther B et al. Dysplasia in Barrett's esophagus. J Cancer Res Clin Oncol 1985;110:145-152.
40. Skinner DB, Walther BC, Riddell RH et al. Barrett's esophagus. Comparison of benign and malignant cases. Ann Surg 1983;198:554-565.
41. Streitz JM Jr., Andrews CW Jr., Ellis FH Jr. Endoscopic surveillance of Barrett's esophagus. Does it help? J Thorac Cardiovasc Surg 1993;105:383-387. (discussion 387-388).
42. Cameron AJ, Carpenter HA. Barrett's esophagus, high-grade dysplasia, and early adenocarcinoma: a pathological study. Am J Gastroenterol 1997;92:586-591.
43. Catrambone G, Leoncini G, Iurilli L et al. [Complications of Barrett's esophagus: indications for esophageal resection with special reference to high-grade dysplasia]. Minerva Chir 1999;54:657-667.
44. Chang LC, Oelschlager BK, Quiroga E et al. Long-term outcome of esophagectomy for high-grade dysplasia or cancer found during surveillance for Barrett's esophagus. J Gastrointest Surg 2006;10:341-346.
45. Falk GW, Rice TW, Goldblum JR, Richter JE. Jumbo biopsy forceps protocol still misses unsuspected cancer in Barrett's esophagus with high-grade dysplasia. Gastrointest Endosc 1999;49:170-176.
46. Ferguson MK, Naunheim KS. Resection for Barrett's mucosa with high-grade dysplasia: implications for prophylactic photodynamic therapy. J Thorac Cardiovasc Surg 1997;114:824-829.
47. Headrick JR, Nichols FC 3rd, Miller DL et al. High-grade esophageal dysplasia: long-term survival and quality of life after esophagectomy. Ann Thorac Surg 2002;73:1697-1702.
48. Incarbone R, Bonavina L, Saino G et al. Outcome of esophageal adenocarcinoma detected during endoscopic biopsy surveillance for Barrett's esophagus. Surg Endosc 2002;16:263-266.
49. Moraca RJ, Low DE. Outcomes and health-related quality of life after esophagectomy for high-grade dysplasia and intramucosal cancer. Arch Surg 2006;141:545-549. (discussion 549-551).
50. Nguyen NT, Schauer P, Luketich JD. Minimally invasive esophagectomy for Barrett's esophagus with high-grade dysplasia. Surgery 2000;127:284-290.
51. Nigro JJ, Hagen JA, DeMeester TR et al. Occult esophageal adenocarcinoma: extent of disease and implications for effective therapy. Ann Surg 1999;230:433-438. (discussion 438-440).
52. Ortiz A, Martinez de Haro LF, Parrilla P et al. Conservative treatment versus antireflux surgery in Barrett's oesophagus: long-term results of a prospective study. Br J Surg 1996;83:274-278.
53. Patti MG, Arcerito M, Feo CV et al. Barrett's esophagus: a surgical disease. J Gastrointest Surg 1999;3:397-403.
54. Prasad GA, Wang KK, Buttar NS et al. Long-term survival following endoscopic and surgical treatment of high-grade dysplasia in Barrett's esophagus. Gastroenterology 2007;132:1226-1233.
55. Reed MF, Tolis G Jr., Edil BH et al. Surgical treatment of esophageal high-grade dysplasia. Ann Thorac Surg 2005;79:1110-1115.
56. Rice TW. Pro: esophagectomy is the treatment of choice for high-grade dysplasia in Barrett's esophagus. Am J Gastroenterol 2006;101:2177-2179.
57. Romagnoli R, Collard JM, Gutschow C et al. Outcomes of dysplasia arising in Barrett's esophagus: a dynamic view. J Am Coll Surg 2003;197:365-371.
58. Sujendran V, Sica G, Warren B, Maynard N. Oesophagectomy remains the gold standard for treatment of high-grade dysplasia in Barrett's oesophagus. Eur J Cardiothorac Surg 2005;28:763-766.
59. Thomson BN, Cade RJ. Oesophagectomy for early adenocarcinoma and dysplasia arising in Barrett's oesophagus. ANZ J Surg 2003;73:121-124.
60. Tseng EE, Wu TT, Yeo CJ, Heitmiller RF. Barrett's esophagus with high grade dysplasia: surgical results and long-term outcome-an update. J Gastrointest Surg 2003;7:164-170.
61. Williams VA, Watson TJ, Herbella FA et al. Esophagectomy for high grade dysplasia is safe, curative, and results in good alimentary outcome. J Gastrointest Surg 2007;11:1589-1597.
62. Zaninotto G, Parenti AR, Ruol A et al. Oesophageal resection for high-grade dysplasia in Barrett's oesophagus. Br J Surg 2000;87:1102-1105.
63. Sigounas D, Christodoulou D, Marcon N, Tsianos EV. Endoscopic mucosal resection-a comprehensive review. Gastric Breast Cancer 2004;3:27-35.
64. Larghi A, Waxman I. State of the art on endoscopic mucosal resection and endoscopic submucosal dissection. Gastrointest Endosc Clin N Am 2007;17:441-469.
65. Larghi A, Lightdale CJ, Memeo L et al. EUS followed by EMR for staging of high-grade dysplasia and early cancer in Barrett's esophagus. Gastrointest Endosc 2005;62:16-23.
66. Bergman JJ. Endoscopic resection for treatment of mucosal Barrett's cancer: time to swing the pendulum. Gastrointest Endosc 2007;65:11-13.
67. Ell C, May A, Pech O et al. Curative endoscopic resection of early esophageal adenocarcinomas (Barrett's cancer). Gastrointest Endosc 2007;65:3-10.
68. Overholt BF, Lightdale CJ, Wang KK et al. Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial. Gastrointest Endosc 2005;62:488-498.
69. Overholt BF, Panjehpour M, Halberg DL. Photodynamic therapy for Barrett's esophagus with dysplasia and/or early stage carcinoma: long-term results. Gastrointest Endosc 2003;58:183-188.
70. Pacifico RJ, Wang KK. Nonsurgical management of Barrett's esophagus with high-grade dysplasia. Surg Oncol Clin N Am 2002;11:321-336.
71. Kimchi ET, Posner MC, Park JO et al. Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation. Cancer Res 2005;65:3146-3154.
72. Fitzgerald RC, Caldas C. Clinical implications of E-cadherin associated hereditary diffuse gastric cancer. Gut 2004;53:775-778.
73. Chung DC, Yoon SS, Lauwers GY, Patel D. Case records of the Massachusetts General Hospital. Case 22-2007. A woman with a family history of gastric and breast cancer. N Engl J Med 2007;357:283-291.
74. Pharoah PD, Guilford P, Caldas C. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology 2001;121:1348-1353.
75. Christofori G, Semb H. The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene. Trends Biochem Sci 1999;24:73-76.
76. Handschuh G, Candidus S, Luber B et al. Tumour-associated E-cadherin mutations alter cellular morphology, decrease cellular adhesion and increase cellular motility. Oncogene 1999;18:4301-4312.
77. Vleminckx K, Vakaet L Jr., Mareel M et al. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 1991;66:107-119.
78. Kaurah P, MacMillan A, Boyd N et al. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA 2007;297:2360-2372.
79. Machado JC, Oliveira C, Carvalho R et al. E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma. Oncogene 2001;20:1525-1528.
80. Tamura G, Yin J, Wang S et al. E-Cadherin gene promoter hypermethylation in primary human gastric carcinomas. J Natl Cancer Inst 2000;92:569-573.
81. Caldas C, Carneiro F, Lynch HT et al. Familial gastric cancer: overview and guidelines for management. J Med Genet 1999;36:873-880.
82. Park JG, Yang HK, Kim WH et al. Report on the first meeting of the International Collaborative Group on Hereditary Gastric Cancer. J Natl Cancer Inst 2000;92:1781-1782.
83. Suriano G, Yew S, Ferreira P et al. Characterization of a recurrent germ line mutation of the E-cadherin gene: implications for genetic testing and clinical management. Clin Cancer Res 2005;11:5401-5409.
84. Brooks-Wilson AR, Kaurah P, Suriano G et al. Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. J Med Genet 2004;41:508-517.
85. Blair V, Martin I, Shaw D et al. Hereditary diffuse gastric cancer: diagnosis and management. Clin Gastroenterol Hepatol 2006;4:262-275.
86. Graziano F, Humar B, Guilford P. The role of the E-cadherin gene (CDH1) in diffuse gastric cancer susceptibility: from the laboratory to clinical practice. Ann Oncol 2003;14:1705-1713.
87. Ikonen T, Matikainen M, Mononen N et al. Association of E-cadherin germ-line alterations with prostate cancer. Clin Cancer Res 2001;7:3465-3471.
88. Richards FM, McKee SA, Rajpar MH et al. Germline E-cadherin gene (CDH1) mutations predispose to familial gastric cancer and colorectal cancer. Hum Mol Genet 1999;8:607-610.
89. Salahshor S, Hou H, Diep CB et al. A germline E-cadherin mutation in a family with gastric and colon cancer. Int J Mol Med 2001;8:439-443.
90. Norton JA, Ham CM, van Dam J et al. CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Ann Surg 2007;245:873-879.
91. Carneiro F, Huntsman DG, Smyrk TC et al. Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening. J Pathol 2004;203:681-687.
92. Charlton A, Blair V, Shaw D et al. Hereditary diffuse gastric cancer: predominance of multiple foci of signet ring cell carcinoma in distal stomach and transitional zone. Gut 2004;53:814-820.
93. Shaw D, Blair V, Framp A et al. Chromoendoscopic surveillance in hereditary diffuse gastric cancer: an alternative to prophylactic gastrectomy? Gut 2005;54:461-468.
94. Chun YS, Lindor NM, Smyrk TC et al. Germline E-cadherin gene mutations: is prophylactic total gastrectomy indicated? Cancer 2001;92:181-187.
95. Gaya DR, Stuart RC, McKee RF et al. E-cadherin mutation-associated diffuse gastric adenocarcinoma: penetrance and non-penetrance. Eur J Gastroenterol Hepatol 2005;17:1425-1428.
96. Huntsman DG, Carneiro F, Lewis FR et al. Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. N Engl J Med 2001;344:1904-1909.
97. Lewis FR, Mellinger JD, Hayashi A et al. Prophylactic total gastrectomy for familial gastric cancer. Surgery 2001;130:612-617. (discussion 617-619).
98. Lynch H, Caldas C, Wirtzfeld D, Vaccaro C, Rubenstein W, Weissman S, Kaurah P, Boyd N, Fitzgerald R, Huntsman D. Hereditary diffuse gastric cancer: Natural history, pathology, screening limitations, and prophylactic total gastrectomy in CDH1 mutation carriers. J Clin Oncol 2007;25:4500.
99. Newman EA, Mulholland MW. Prophylactic gastrectomy for hereditary diffuse gastric cancer syndrome. J Am Coll Surg 2006;202:612-617.
100. Park J, Gores GJ, Patel T. Lipopolysaccharide induces cholangiocyte proliferation via an interleukin-6-mediated activation of p44/p42 mitogen-activated protein kinase. Hepatology 1999;29:1037-1043.
101. Chapman RW. Risk factors for biliary tract carcinogenesis. Ann Oncol 1999;10(Suppl 4):308-311.
102. Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2002;2:10.
103. Todani T, Watanabe Y, Narusue M et al. Congenital bile duct cysts: classification, operative procedures, and review of thirty-seven cases including cancer arising from choledochal cyst. Am J Surg 1977;134:263-269.
104. Lenriot JP, Gigot JF, Segol P et al. Bile duct cysts in adults: a multi-institutional retrospective study. French Associations for Surgical Research. Ann Surg 1998;228:159-166.
105. Voyles CR, Smadja C, Shands WC, Blumgart LH. Carcinoma in choledochal cysts. Age-related incidence. Arch Surg 1983;118:986-988.
106. Benjamin IS. Biliary cystic disease: the risk of cancer. J Hepatobiliary Pancreat Surg 2003;10:335-339.
107. Todani T, Watanabe Y, Toki A, Urushihara N. Carcinoma related to choledochal cysts with internal drainage operations. Surg Gynecol Obstet 1987;164:61-64.
108. Watanabe Y, Toki A, Todani T. Bile duct cancer developed after cyst excision for choledochal cyst. J Hepatobiliary Pancreat Surg 1999;6:207-212.
109. O'Mahony CA, Vierling JM. Etiopathogenesis of primary sclerosing cholangitis. Semin Liver Dis 2006;26:3-21.
110. Levy C, Lindor KD. Primary sclerosing cholangitis: epidemiology, natural history, and prognosis. Semin Liver Dis 2006;26:22-30.
111. Narayanan Menon KV, Wiesner RH. Etiology and natural history of primary sclerosing cholangitis. J Hepatobiliary Pancreat Surg 1999;6:343-351.
112. Burak K, Angulo P, Pasha TM et al. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 2004;99:523-526.
113. Holzinger F, Z'Graggen K, Buchler MW. Mechanisms of biliary carcinogenesis: a pathogenetic multi-stage cascade towards cholangiocarcinoma. Ann Oncol 1999;10(Suppl 4):122-126.
114. Fleming KA, Boberg KM, Glaumann H et al. Biliary dysplasia as a marker of cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol 2001;34:360-365.
115. Martins EB, Fleming KA, Garrido MC et al. Superficial thrombophlebitis, dysplasia, and cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology 1994;107:537-542.
116. Bergquist A, Glaumann H, Stal P et al. Biliary dysplasia, cell proliferation and nuclear DNA-fragmentation in primary sclerosing cholangitis with and without cholangiocarcinoma. J Intern Med 2001;249:69-75.
117. Harrison PM. Diagnosis of primary sclerosing cholangitis. J Hepatobiliary Pancreat Surg 1999;6:356-360.
118. Rosen CB, Nagorney DM. Cholangiocarcinoma complicating primary sclerosing cholangitis. Semin Liver Dis 1991;11:26-30.
119. Kitiyakara T, Chapman RW. Chemoprevention and screening in primary sclerosing cholangitis. Postgrad Med J 2008;84:228-237.
120. Patt CH, Thuluvath PJ. Liver transplanatation for primary sclerosing cholangitis: screening for biliary malignancy and the role of preemptive transplantation. Cur Opin Organ Transplant 2002;7:129-136.
121. Goss JA, Shackleton CR, Farmer DG et al. Orthotopic liver transplantation for primary sclerosing cholangitis. A 12-year single center experience. Ann Surg 1997;225:472-481.
122. Iwatsuki S, Todo S, Marsh JW et al. Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation. J Am Coll Surg 1998;187:358-364.
123. Levy C, Lymp J, Angulo P et al. The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci 2005;50:1734-1740.
124. Rea DJ, Heimbach JK, Rosen CB et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg 2005;242:451-458. (discussion 458-461).
125. Levin B. An overview of preventive strategies for pancreatic cancer. Ann Oncol 1999;10(Suppl 4):193-196.
126. Hall Pde L, Wilentz RE, de Klerk W, Bornman PP. Premalignant conditions of the pancreas. Pathology 2002;34:504-517.
127. Luttges J, Kloppel G. Precancerous conditions of pancreatic carcinoma. J Hepatobiliary Pancreat Surg 2000;7:568-574.
128. Wilentz RE, Iacobuzio-Donahue CA, Argani P et al. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res 2000;60:2002-2006.
129. Rieder H, Bartsch DK. Familial pancreatic cancer. Familial Cancer 2004;3:69-74.
130. Ehrenthal D, Haeger L, Griffin T, Compton C. Familial pancreatic adenocarcinoma in three generations. A case report and a review of the literature. Cancer 1987;59:1661-1664.
131. Banke MG, Mulvihill JJ, Aston CE. Inheritance of pancreatic cancer in pancreatic cancer-prone families. Med Clin North Am 2000;84:677-690. x-xi.
132. Hahn SA, Greenhalf B, Ellis I et al. BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 2003;95:214-221.
133. Tersmette AC, Petersen GM, Offerhaus GJ et al. Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. Clin Cancer Res 2001;7:738-744.
134. Boardman LA, Thibodeau SN, Schaid DJ et al. Increased risk for cancer in patients with the Peutz-Jeghers syndrome. Ann Intern Med 1998;128:896-899.
135. Giardiello FM, Welsh SB, Hamilton SR et al. Increased risk of cancer in the Peutz-Jeghers syndrome. N Engl J Med 1987;316:1511-1514.
136. Vasen HF, Gruis NA, Frants RR et al. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer 2000;87:809-811.
137. Ferrone CR, Levine DA, Tang LH et al. BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. J Clin Oncol 2009;27:433-438.
138. Kim MP, Evans DB, Vu TM, Fleming JB. The recognition and surgical management of heritable lesions of the pancreas. Surg Oncol Clin N Am 2009;18:99-119. ix.
139. Tanaka M, Chari S, Adsay V et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 2006;6:17-32.
140. Khalid A, McGrath KM, Zahid M et al. The role of pancreatic cyst fluid molecular analysis in predicting cyst pathology. Clin Gastroenterol Hepatol 2005;3:967-973.
141. Brugge WR, Lewandrowski K, Lee-Lewandrowski E et al. Diagnosis of pancreatic cystic neoplasms: a report of the cooperative pancreatic cyst study. Gastroenterology 2004;126:1330-1336.
142. Brugge WR. Should all pancreatic cystic lesions be resected? Cyst-fluid analysis in the differential diagnosis of pancreatic cystic lesions: a meta-analysis. Gastrointest Endosc 2005;62:390-391.
143. Vin Y, Sima CS, Getrajdman GI et al. Management and outcomes of postpancreatectomy fistula, leak, and abscess: results of 908 patients resected at a single institution between 2000 and 2005. J Am Coll Surg 2008;207:490-498.
144. Tsiotos GG, Farnell MB, Sarr MG. Are the results of pancreatectomy for pancreatic cancer improving? World J Surg 1999;23:913-919.
145. Yeo CJ, Cameron JL, Sohn TA et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg 1997;226:248-257. (discussion 257-260).
146. Allen PJ, D'Angelica M, Gonen M et al. A selective approach to the resection of cystic lesions of the pancreas: results from 539 consecutive patients. Ann Surg 2006;244:572-582.
147. Allen PJ, Jaques DP, D'Angelica M et al. Cystic lesions of the pancreas: selection criteria for operative and nonoperative management in 209 patients. J Gastrointest Surg 2003;7:970-977.
148. Jang JY, Kim SW, Lee SE et al. Treatment guidelines for branch duct type intraductal papillary mucinous neoplasms of the pancreas: when can we operate or observe? Ann Surg Oncol 2008;15:199-205.
149. Lee CJ, Scheiman J, Anderson MA et al. Risk of malignancy in resected cystic tumors of the pancreas < or = 3 cm in size: is it safe to observe asymptomatic patients? A multi-institutional report. J Gastrointest Surg 2008;12:234-242.
150. Lee SH, Shin CM, Park JK et al. Outcomes of cystic lesions in the pancreas after extended follow-up. Dig Dis Sci 2007;52:2653-2659.
151. Pelaez-Luna M, Chari ST, Smyrk TC et al. Do consensus indications for resection in branch duct intraductal papillary mucinous neoplasm predict malignancy? A study of 147 patients. Am J Gastroenterol 2007;102:1759-1764.
152. Rodriguez JR, Salvia R, Crippa S et al. Branch-duct intraductal papillary mucinous neoplasms: observations in 145 patients who underwent resection. Gastroenterology 2007;133:72-79. (quiz 309-310).
153. Fritz S, Warshaw AL, Thayer SP. Management of mucin-producing cystic neoplasms of the pancreas. Oncologist 2009;14:125-136.
154. Roggin KK, Rudloff U, Blumgart LH, Brennan MF. Central pancreatectomy revisited. J Gastrointest Surg 2006;10:804-812.
155. Bendix Holme J, Jacobsen N, Rokkjaer M, Kruse A. Total pancreatectomy in six patients with intraductal papillary mucinous tumour of the pancreas: the treatment of choice. HPB (Oxford) 2001;3:257-262.
156. Chari ST, Yadav D, Smyrk TC et al. Study of recurrence after surgical resection of intraductal papillary mucinous neoplasm of the pancreas. Gastroenterology 2002;123:1500-1507.
157. Ortner MA, Dorta G, Blum AL, Michetti P. Endoscopic interventions for preneoplastic and neoplastic lesions: mucosectomy, argon plasma coagulation, and photodynamic therapy. Dig Dis 2002;20:167-172.
158. Conio M, Repici A, Cestari R et al. Endoscopic mucosal resection for high-grade dysplasia and intramucosal carcinoma in Barrett's esophagus: an Italian experience. World J Gastroenterol 2005;11:6650-6655.
159. van Kouwen MC, Drenth JP, Oyen WJ et al. [18F]Fluoro-2-deoxy-D-glucose positron emission tomography detects gastric carcinoma in an early stage in an asymptomatic E-cadherin mutation carrier. Clin Cancer Res 2004;10:6456-6459.
160. Hruban RH, Canto MI, Yeo CJ. Prevention of pancreatic cancer and strategies for management of familial pancreatic cancer. Dig Dis 2001;19:76-84.
161. Giardiello FM, Brensinger JD, Tersmette AC et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 2000;119:1447-1453.
162. Ulrich CD. Pancreatic cancer in hereditary pancreatitis: consensus guidelines for prevention, screening and treatment. Pancreatology 2001;1:416-422.
163. Goldstein AM, Fraser MC, Struewing JP et al. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med 1995;333:970-974.
164. Bansal P, Sonnenberg A. Pancreatitis is a risk factor for pancreatic cancer. Gastroenterology 1995;109:247-251.
165. Lowenfels AB, Maisonneuve P, Cavallini G et al. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med 1993;328:1433-1437.